ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will participate in the Morgan Stanley Global Healthcare Conference. Consistent with the Conference’s format, ImmunoGen President and CEO Daniel Junius will discuss the Company in a moderated question and answer session that will be webcast beginning at 9:55am ET on September 8, 2014.

This webcast will be accessible live through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week.

The Company also will be participating in one-on-one meetings at the 9th Annual Citi Biotech Conference September 4, 2014 in Boston, MA.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product with ImmunoGen’s ADC technology is Roche’s Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in clinical testing through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

For Investors:ImmunoGen, Inc.Carol Hausner, [e-mail] Media:Pure Communications, Inc.Dan Budwick, 973-271-6085